Cilostazol effective drug in preventing stroke in men than women

Dual antiplatelet therapy (DAPT) is highly effective in preventing atherothrombotic complications in patients with previous myocardial infarction and current guidelines recommend the prescription of DAPT for at least 12 months in all patients experiencing an acute event. now, Long-term dual antiplatelet therapy (DAPT) using cilostazol significantly reduces recurrent ischemic stroke in men, but not in women as reported in the studywhich was presented at the International Stroke Conference.

The results were drawn based on about 2000 patients in the Cilostazol Stroke Prevention Study Combination who received dual antiplatelet therapy using cilostazol, compared with men who received monotherapy. In contrast, the rate of recurrent stroke was not significantly different between women who received dual antiplatelet therapy using cilostazol and those who received monotherapy.